Site for Registry of Asthma Patients Initiating

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Asthma
Age: Between 12 Year(s) - 99 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Initiating treatment with DUPIXENT for a primary indication of asthma according to the country-specific prescribing information
2. Willing and able to comply with the required clinic visits, study procedures and assessments
3. Able to understand and complete study-related questionnaires
4. Provide signed informed consent; for patients under the age of 18, both parental (legal guardian) consent and patient assent are required

You may not be eligible for this study if the following are true:

1. Patients who have a contraindication to DUPIXENT according to the country-specific prescribing information
2. Treatment with dupilumab within 6 months before the screening visit, or within 6 months of the baseline visit if the screening and baseline occur on the same day
3. Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other medical, social, or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies